Kladribin

Kladribin
Klinički podaci
Prodajno ime	Leustatin, Mylinax
Drugs.com	Monografija
Način primene	Intravenozno
Identifikatori
CAS broj	4291-63-8
ATC kod	L01BB04 (WHO)
PubChem	CID 20279
DrugBank	DB00242
ChemSpider	19105
ChEBI	CHEBI:567361
ChEMBL	CHEMBL1619

Kladribin je organsko jedinjenje, koje sadrži 10 atoma ugljenika i ima molekulsku masu od 285,687 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	7
Broj donora vodonika	3
Broj rotacionih veza	2
Particioni koeficijent^[10] (ALogP)	-0,3
Rastvorljivost^[11] (logS, log(mol/L))	-1,3
Polarna površina^[12] (PSA, Å²)	119,3

Reference

^ Warnke, C.; Wiendl, H.; Hartung, H. P.; Stüve, O.; Kieseier, B. C. (2010). „Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine”. Drug Design, Development and Therapy. 4: 117—126. PMC 2915536 . PMID 20689698. doi:10.2147/dddt.s6627 .
^ Sigal, D. S.; Miller, H. J.; Schram, E. D.; Saven, A. (2010). „Beyond hairy cell: The activity of cladribine in other hematologic malignancies”. Blood. 116 (16): 2884—2896. PMID 20634380. doi:10.1182/blood-2010-02-246140.
^ Khalid BA; Hamilton NT; Cauchi MN (јануар 1976). „Binding of thyroid microsomes by lymphocytes from patients with thyroid disease and normal subjects”. Clin Exp Immunol. 23 (1): 28—32. PMC 1538364 . PMID 1261088.
^ Sampat K; Kantarjian H; Borthakur G (октобар 2009). „Clofarabine: emerging role in leukemias”. Expert Opin Investig Drugs. 18 (10): 1559—64. PMID 19715446. doi:10.1517/13543780903173222.
^ Kantarjian HM; Jeha S; Gandhi V; Wess M; Faderl S (октобар 2007). „Clofarabine: past, present, and future”. Leuk Lymphoma. 48 (10): 1922—30. PMID 17852710. doi:10.1080/10428190701545644.
^ Zhenchuk, A.; Lotfi, K.; Juliusson, G.; Albertioni, F. (2009). „Mechanisms of anti-cancer action and pharmacology of clofarabine”. Biochemical Pharmacology. 78 (11): 1351—9. PMID 19576186. doi:10.1016/j.bcp.2009.06.094.
^ Larson ML, Venugopal P (јун 2009). „Clofarabine: a new treatment option for patients with acute myeloid leukemia”. Expert Opin Pharmacother. 10 (8): 1353—7. PMID 19463072. doi:10.1517/14656560902997990.
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

Literatura

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.

Spoljašnje veze

Cladribine Архивирано на веб-сајту Wayback Machine (17. април 2014)

Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).

[1] Warnke, C.; Wiendl, H.; Hartung, H. P.; Stüve, O.; Kieseier, B. C. (2010). „Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine”. Drug Design, Development and Therapy. 4: 117—126. PMC 2915536 . PMID 20689698. doi:10.2147/dddt.s6627 .

[2] Sigal, D. S.; Miller, H. J.; Schram, E. D.; Saven, A. (2010). „Beyond hairy cell: The activity of cladribine in other hematologic malignancies”. Blood. 116 (16): 2884—2896. PMID 20634380. doi:10.1182/blood-2010-02-246140.

[3] Khalid BA; Hamilton NT; Cauchi MN (јануар 1976). „Binding of thyroid microsomes by lymphocytes from patients with thyroid disease and normal subjects”. Clin Exp Immunol. 23 (1): 28—32. PMC 1538364 . PMID 1261088.

[4] Sampat K; Kantarjian H; Borthakur G (октобар 2009). „Clofarabine: emerging role in leukemias”. Expert Opin Investig Drugs. 18 (10): 1559—64. PMID 19715446. doi:10.1517/13543780903173222.

[5] Kantarjian HM; Jeha S; Gandhi V; Wess M; Faderl S (октобар 2007). „Clofarabine: past, present, and future”. Leuk Lymphoma. 48 (10): 1922—30. PMID 17852710. doi:10.1080/10428190701545644.

[6] Zhenchuk, A.; Lotfi, K.; Juliusson, G.; Albertioni, F. (2009). „Mechanisms of anti-cancer action and pharmacology of clofarabine”. Biochemical Pharmacology. 78 (11): 1351—9. PMID 19576186. doi:10.1016/j.bcp.2009.06.094.

[7] Larson ML, Venugopal P (јун 2009). „Clofarabine: a new treatment option for patients with acute myeloid leukemia”. Expert Opin Pharmacother. 10 (8): 1353—7. PMID 19463072. doi:10.1517/14656560902997990.

[8] Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.

[9] Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.

[10] Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.

[11] Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.

[12] Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

p r u Citostatici-antitumorski lekovi
Alkilirajuća sredstva	ciklofosfamid • ifosfamid • temozolomid • dakarbazin
Antimetaboliti	metotreksat • pemetreksed • kladribin • fludarabin • citarabin • fluorouracil • gemcitabin • kapecitabin
Protivtumorski antibiotici	doksorubicin • daunorubicin • idarubicin • bleomicin
Sredastva biljnog porekla	vinblastin • vinkristin • vinorelbin • etopozid • paklitaksel • docetaksel
Hormonski lekovi	megestrol • medroksiprogesteron • goserelin • triptorelin • tamoksifen • flutamid • nilutamid • bikalutamid • anastrozol • letrozol • eksemestan
Ostali najnoviji lekovi	cisplatin • karboplatin • oksaliplatin • rituksimab • alemtuzumab • cetuksimab • bevacizumab • imatinib • gefitinib • erlotinib • sorafenib • estramustin • tretinoin • bortezomib • anagrelid